Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 4/2010

01-12-2010 | Letter to the Editor

Other malignancies in patients with breast cancer: a single institute experience

Authors: Erkan Dogan, Sercan Aksoy, Omer Dizdar, Didem S. Dede, Cagatay Arslan, Yavuz Ozisik, Kadri Altundag

Published in: Medical Oncology | Issue 4/2010

Login to get access

Excerpt

To The Editor, …
Literature
1.
Kirova YM, et al. Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer. 2008;98:870–4.CrossRefPubMed
2.
Turner BC, Harrold E, Matloff E, et al. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. J Clin Oncol. 1999;17:3017–24.PubMed
3.
Ewertz M, Mouridsen HT. Second cancer following cancer of the female breast in Denmark, 1943–80. Natl Cancer Inst Monogr. 1985;68:325–9.PubMed
Metadata
Title
Other malignancies in patients with breast cancer: a single institute experience
Authors
Erkan Dogan
Sercan Aksoy
Omer Dizdar
Didem S. Dede
Cagatay Arslan
Yavuz Ozisik
Kadri Altundag
Publication date
01-12-2010
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2010
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9368-8

Other articles of this Issue 4/2010

Medical Oncology 4/2010 Go to the issue

Original Paper

The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater

Original Paper

Novel amino-modified silica nanoparticles as efficient vector for hepatocellular carcinoma gene therapy

Original Paper

Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma

Original Paper

Protective effects of propolis and related polyphenolic/flavonoid compounds against toxicity induced by irinotecan

Original Paper

Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA)

Letter to the Editor

Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits